Thermo Fisher – Outsourced CGT Manufacturing & Expansion Opportunities – 7 December 2021

  • Public Equity
  • Healthcare
  • North America


Former senior director at Thermo Fisher


  • Recent developments in CGT (cell and gene therapy) outsourcing trends, including where CDMOs (contract development and manufacturing organisations) could capture market share
  • Expected gaps in Thermo Fisher’s (NYSE: TMO) offerings
  • Thermo Fisher’s acquisition of PPD and potential for further M&A
  • Thermo Fisher's potential areas for expansion – pre-clinical, post-commercial and cryopreservation
  • Industry outlook and growth expectations, highlighting lead times and labour dynamics


Gain access to Premium Content

Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.

    One week, unlimited access to over 25,000 transcripts
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited